Entero Healthcare Solutions Ltd. (ENTERO) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Entero Healthcare Solutions Ltd. stock ₹549, price ₹2,115, that is 74.0% below the price, quality 39 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
33‑month range ₹949.20 – ₹2,115 · fair‑value band ₹246.25 – ₹726.17 · the ₹2,115 price screens above the ₹548.95 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Entero Healthcare Solutions in your weekly email
Every Wednesday you see whether Entero Healthcare Solutions is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India.
Show moreShow less
The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics.
It also provides nebulizers, personal protective, hygiene and surgical consumable products, homecare medical devices, gloves and mobility equipment, digital thermometers.
In addition, the company offers healthcare products, including pharmaceutical and nutraceutical products, vaccines, medical devices, such as orthopaedic implants and coronary stents, and hospital consumables comprising examination and surgical gloves, syringes, needles and sutures to hospitals, retail pharmacies, healthcare product manufacturers, and healthcare clinics.
Entero Healthcare Solutions Limited was incorporated in 2018 and is based in Mumbai, India.
Stock analysis
Entero Healthcare Solutions Ltd. (ENTERO) currently trades at ₹2,115, while our model-based Fair Value estimate is ₹548.95, 74% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹971.53 per share, and 0 of the 23 models we run sit above the ₹2,115 price.
Bear case: the Growth DCF group reads lowest at ₹136.94, and 23 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹246.25 (bear) to ₹726.17 (bull), the price of ₹2,115 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Entero Healthcare Solutions Ltd. reported revenue of ₹65.9B in FY2025 versus ₹25.2B in FY2021, a compound +27.2%/yr. Reported net income was ₹1.2B in FY2025.
Key figures
Market cap ₹92.1B (≈ $981M) Small · P/E ratio 66.2 · P/S ratio 1.53 · EPS (TTM) ₹31.97 · Net margin 1.8% · Return on equity 10.5% · Return on assets (EBIT) 3.7% (5-year average) · Operating margin 4.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and 123% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −74%, ENTERO screens richer than that median.
Fair Value models
Bear₹246.25Fair Value ₹548.95Bull₹726.17
Price ₹2,115 · Downside -74.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹31.97 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+29.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.3%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+56.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+56.3%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 3%
2025 sits 62% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Compare Entero Healthcare Solutions Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−74.0% · Bottom 25%
Profitability
Return on equity (12 months)10.5% · Top 25%
Return on assets4.1% · Above median
Net margin (12 months)2.3% · Above median
Operating margin (12 months)4.7% · Above median
Growth and dividend
Revenue growth (quarter YoY)32.9% · Top 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
P/E (12 months)66.2× · Priciest 25%
P/B5.46× · Priciest 25%
P/S (12 months)1.53× · Priciest 25%
EV/EBITDA35.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 39
FUTURE (revenue growth)100· sector 21
PAST (return on equity)42· sector 26
HEALTH (low debt)96· sector 96
DIVIDEND (yield)0· sector 54
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Entero Healthcare Solutions Ltd. (ENTERO) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of ₹548.95 versus a price of ₹2,115, about 74% lower (overvalued).
What is the fair value of ENTERO?
Our model-based fair value for Entero Healthcare Solutions Ltd. is ₹548.95 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹2,115.
What is the quality score of ENTERO?
Entero Healthcare Solutions Ltd. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Entero Healthcare Solutions Ltd. (ENTERO)?
Our model-based price target is the fair value of ₹548.95 (as of Nov 10, 2026) from 23 valuation models. Cautious scenario ₹246.25, optimistic scenario ₹726.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Entero Healthcare Solutions Ltd. stock forecast for 2026?
Our models put fair value at ₹548.95, about 74% lower versus a price of ₹2,115 (overvalued). Cautious scenario ₹246.25, optimistic scenario ₹726.17. The calculation is refreshed regularly with new filings.
What is the revenue of Entero Healthcare Solutions Ltd. (ENTERO)?
Entero Healthcare Solutions Ltd. reported trailing-twelve-month revenue of about ₹76.4B (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Entero Healthcare Solutions Ltd. (ENTERO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Entero Healthcare Solutions Ltd. it is ₹548.95 per share (as of Nov 10, 2026), against a price of ₹2,115. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Entero Healthcare Solutions Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, ENTERO trades above its calculated fair value: price ₹2,115, fair value ₹548.95, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENTERO?
No. The price is what the market pays today (₹2,115); the fair value is what the company's own numbers justify (₹548.95). For Entero Healthcare Solutions Ltd. the two are ₹1,566 per share apart. That gap is exactly why we show both numbers side by side.
How much is Entero Healthcare Solutions Ltd. worth?
The market values Entero Healthcare Solutions Ltd. at about ₹92.1B (market capitalisation, as of Nov 10, 2026). Per share that is ₹2,115; our models calculate a fair value of ₹548.95 per share.
What do the bullish and bearish scenarios say about ENTERO?
Our models span a range for Entero Healthcare Solutions Ltd.: cautious scenario ₹246.25, base ₹548.95, optimistic ₹726.17 per share (as of Nov 10, 2026, price ₹2,115). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ENTERO?
Entero Healthcare Solutions Ltd. trades at a price-to-earnings ratio of 66.2 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹548.95 is built from several models across several years. Other multiples: P/B 5.5, P/S 1.5, EV/EBITDA 35.0.
How solid is the balance sheet of Entero Healthcare Solutions Ltd. (ENTERO)?
Balance-sheet figures for Entero Healthcare Solutions Ltd. (as of Nov 10, 2026): return on equity 10.5%, debt of 0.07 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is ENTERO from its 52-week high?
Entero Healthcare Solutions Ltd. trades at ₹2,115, at its 52-week high of ₹2,115 and 123% above the low of ₹949.20 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹548.95 is for.
Which stocks are comparable to Entero Healthcare Solutions Ltd.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Entero Healthcare Solutions Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price ₹2,115, calculated fair value ₹548.95 (−74%), Quality Score 39/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENTERO calculated?
We run Entero Healthcare Solutions Ltd. through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹548.95 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Entero Healthcare Solutions Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Entero Healthcare Solutions Ltd. (ENTERO)?
The closing price on Nov 9, 2026 was ₹2,115. Our model-based fair value is ₹548.95, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Entero Healthcare Solutions Ltd. right now?
The price sits above even our optimistic bull case (₹726.17). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (₹246.25 to ₹726.17). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Entero Healthcare Solutions Ltd.
How large is the market capitalisation of Entero Healthcare Solutions Ltd. (ENTERO)?
The market capitalisation of Entero Healthcare Solutions Ltd. is ₹92.1B (≈ $981M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Entero Healthcare Solutions Ltd. (ENTERO)?
The price-to-sales ratio of Entero Healthcare Solutions Ltd. is 1.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Entero Healthcare Solutions Ltd. (ENTERO)?
Earnings per share at Entero Healthcare Solutions Ltd. are ₹31.97 (price ÷ EPS = P/E 66.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Entero Healthcare Solutions Ltd. (ENTERO)?
The net margin of Entero Healthcare Solutions Ltd. is 1.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Entero Healthcare Solutions Ltd. (ENTERO)?
The return on equity (ROE) of Entero Healthcare Solutions Ltd. is 10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Entero Healthcare Solutions Ltd. (ENTERO)?
On an EBIT basis the return on assets of Entero Healthcare Solutions Ltd. is 3.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Entero Healthcare Solutions Ltd. (ENTERO)?
The operating margin of Entero Healthcare Solutions Ltd. is 4.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Entero Healthcare Solutions Ltd. (ENTERO)?
Revenue at Entero Healthcare Solutions Ltd. is growing +32.9% versus a year earlier (3y avg +25.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Entero Healthcare Solutions Ltd. (ENTERO)?
Earnings per share at Entero Healthcare Solutions Ltd. are growing +44.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Entero Healthcare Solutions Ltd. (ENTERO) generate?
The free cash flow of Entero Healthcare Solutions Ltd. is ₹17.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Entero Healthcare Solutions Ltd. (ENTERO) carry?
The net debt of Entero Healthcare Solutions Ltd. is ₹5.2B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Entero Healthcare Solutions Ltd. in the live analysis
One click puts Entero Healthcare Solutions Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 10, 2026